LeanBioPro — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

LeanBioPro is a privately held, revenue-generating CDMO that provides comprehensive biopharmaceutical development and manufacturing services. The company operates with a 'lean thinking' philosophy to enhance efficiency and offers technological platforms for microbial, mammalian, pDNA, and mRNA production. With a new GMP facility expansion underway in Barcelona (operational Q4 2025/Q1 2026) and a track record of shepherding over 100 molecules to advanced clinical stages, Leanbio is positioning itself as a key partner for biotech startups and pharmaceutical companies. Its service-based model is supported by recent public funding and significant private investment into capacity expansion.

BiologicsAntibodies

Technology Platform

Multi-platform CDMO offering microbial (E. coli, P. pastoris), mammalian (CHO), plasmid DNA (pDNA), and mRNA expression systems for end-to-end development and GMP manufacturing of biologics, including mAbs, bispecifics, enzymes, ADCs, and nucleic acid therapies.

Opportunities

The global surge in biologics and advanced therapies (mRNA, pDNA, ADCs) creates sustained demand for specialized CDMO capacity.

Leanbio's new GMP facility expansion (€20M investment) directly addresses industry-wide manufacturing shortages, positioning it to capture larger, later-stage commercial contracts.

Its proven expertise in mRNA, supported by recent public funding, aligns with a high-growth therapeutic modality.

Risk Factors

Intense competition from large global CDMOs and niche players requires constant differentiation.

Execution risk surrounds the timely and on-budget completion of its critical new GMP facility.

Revenue is dependent on client program success, exposing the company to pipeline delays or cancellations in the biotech sector.

Competitive Landscape

Leanbio competes in a fragmented but competitive global CDMO market. It faces large, capital-rich players like Lonza, Catalent, and Fujifilm Diosynth, as well as many regional and specialized competitors. Its differentiation lies in its multi-platform versatility, 'lean' operational focus, and specific expertise in microbial systems and emerging mRNA/pDNA manufacturing within the European biotech hub of Barcelona.

More companies in Biologics / Biosimilars →More companies in Spain →